Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report). The company’s ...

Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of ...

Investing.com - Edgewise Therapeutics (NASDAQ: EWTX) reported fourth quarter EPS of $-0.34, in line with the analyst estimate of $-0.34. Revenue for the quarter came ...

Piper Sandler has maintained a confident stance on Edgewise Therapeutics (NASDAQ: EWTX), reiterating an Overweight rating with a $48.00 price target. The firm's optimism is tied ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Edgewise Therapeutics. “This landmark study presents compelling biomarker data and promising signals that… The venture philanthropy organization SOLVE FSHD is offering $10 million in prizes for ...